An anti-inflammatory drug from Novo Nordisk unexpectedly failed in a Phase 3 study that aimed to prove a link between cardiovascular inflammation and heart disease.
July 31, 2026 11:35 AM EDT
Novo Nordisk rocked by late-stage cardiovascular drug failure
Elizabeth Cairns
Senior biopharma journalist
An anti-inflammatory drug from Novo Nordisk unexpectedly failed in a Phase 3 study that aimed to prove a link between cardiovascular inflammation and heart disease …
Novo Nordisk inflammation-targeting drug misses mark in heart disease study
Novo Nordisk shares dive 9% after heart medicine fails trial
Novo setback casts doubt on a new way to treat heart disease
Novo Nordisk Says Anti-Inflammatory Drug Trial Fails to Cut Cardiovascular Risk in High Risk Patients - N
Is Novo Nordisk Stock (NVO) a Good Buy After Today’s Plunge?
Novo Nordisk’s Market Value Sheds $30 Billion—Here’s Why Shares Are Down
Novo Nordisk: Wirkstoff Ziltivekimab ist ein Entwicklungs-Fehlschlag
A Novo Nordisk drug missed the mark in a heart disease study, raising questions about targeting inflammation to prevent…
The experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse…
Ziltivekimab's failure in a key trial spurred share sell-offs for Novo and other biotechs, as it suggested trouble for different…
Novo Nordisk Phase 3 ZEUS trial shows ziltivekimab missed MACE risk reduction. Operating profit outlook unchanged despite Q3…
The company said the weight loss and diabetes treatment drug failed to show any significant reduction in the progression of…
Shares of Novo Nordisk plunged after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's…
